CTS Corporation (CTS) Q3 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 28 2025
0mins
Should l Buy CTS?
Source: SeekingAlpha
Sales Sales in the third quarter were $143 million, up 8% from $132 million in the third quarter of 2024. Diversified end market sales increased 22% year-over-year, while transportation sales were down 7% from the same period last year due to softness in commercial vehicle products.
Gross Margin Adjusted gross margin was 38.9% in the third quarter, up 66 basis points compared to the third quarter of 2024. This improvement was attributed to operational execution and minimal impact from tariffs.
Adjusted EBITDA Adjusted EBITDA was 23.8% in the quarter, a reduction of 55 basis points compared to the third quarter of 2024, but an improvement of 86 basis points sequentially. The year-over-year reduction was not explicitly explained.
Adjusted Diluted Earnings Per Share Adjusted diluted earnings were $0.60 per share, down from $0.61 in the third quarter of 2024. The decrease was primarily due to an unfavorable impact from recent U.S. tax legislation.
Operating Cash Flow Operating cash flow in the third quarter was $29 million, down from $35 million in the third quarter of 2024. The reasons for this decline were not explicitly mentioned.
SyQwest Sales SyQwest sales were $8.8 million during the quarter, contributing to the growth in aerospace and defense sales, which were up 23% year-over-year.
Transportation Sales Transportation sales were $58.5 million in the third quarter, down approximately 7% from the same period last year due to softness in commercial vehicle products.
Aerospace and Defense Sales Aerospace and defense sales in the third quarter were up 23% from the third quarter of 2024. This growth was supported by SyQwest revenues and multiple orders for sonar applications.
Industrial Market Sales Sales in the industrial market were up 21% year-over-year and 9% sequentially, driven by a steady recovery with OEMs and distribution customers.
Medical End Market Sales Medical end market sales were up 22% compared to the same period in 2024, with strong demand for minimally invasive applications and therapeutic products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTS
About CTS
CTS Corporation is a global manufacturer of sensors, connectivity components, and actuators. The Company designs, manufactures, and sells a broad line of sensors, connectivity components, and actuators primarily to original equipment manufacturers (OEMs), suppliers for the aerospace and defense, industrial, medical, and transportation markets, and the United States Government. The Company's devices are categorized by their ability to Sense, Connect or Move. Sense products provide vital inputs to electronic systems. Connect products allow systems to function in synchronization with other systems. Move products ensure the required movements are effectively and accurately executed. Its Sense products include Controls, Pedals, Piezo Sensing Products, Sensors, Switches and Transducers. Its Connect products include EMI/RFI Filters, Capacitors, Frequency Control Products, Resistors and RF filters. The Company's Move products include Piezo Microactuators and Rotary Actuators.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CTS Corporation Q1 2026 Earnings Call Insights
- Significant Sales Growth: CTS Corporation reported Q1 sales of $139 million, an 11% increase compared to Q1 2025, with diversified markets up 18% and transportation sales growing by 3%, indicating strong performance in diversified sectors.
- Margin Improvement: The adjusted diluted earnings per share for Q1 reached $0.62, up from $0.44 in Q1 2025, with gross margin expanding by 250 basis points to 39.5%, reflecting a notable enhancement in profitability.
- Strong Medical Market: Sales in the medical sector reached $25 million, a 28% year-over-year increase, indicating robust demand and an expectation for continued double-digit growth, which will further drive company performance.
- Tightened 2026 Outlook: The company narrowed its 2026 sales guidance to a range of $560 million to $580 million, with adjusted EPS expectations of $2.35 to $2.45, demonstrating management's confidence in future market conditions while maintaining cautious optimism regarding performance.
See More
CTS Corporation Q1 2026 Earnings Exceed Expectations
- Earnings Beat: CTS Corporation reported a Q1 2026 non-GAAP EPS of $0.62, exceeding estimates by $0.10, which reflects the company's strong profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved $139 million in revenue for the first quarter, marking a 10.3% year-over-year increase, with sales to diversified end-markets rising by 18%, indicating successful implementation of its market diversification strategy.
- Guidance Adjustment: CTS has narrowed its 2026 sales guidance from a range of $550-$580 million to $560-$580 million, while adjusting its diluted EPS forecast from $2.30-$2.45 to $2.35-$2.45, reflecting an optimistic outlook for future market conditions.
- Stable Transportation Market: Although sales in the transportation market grew by only 3%, CTS's strong performance in diversified markets demonstrates the effectiveness of its strategic positioning, laying a solid foundation for continued growth.
See More
CTS Corporation Narrows 2026 Sales Guidance
- Sales Guidance Adjustment: CTS Corporation has narrowed its 2026 sales guidance from $550-$580 million to $560-$580 million, indicating increased confidence in future market conditions, which may bolster investor sentiment.
- Earnings Per Share Upgrade: The company has revised its adjusted EPS forecast from $2.30-$2.45 to $2.35-$2.45, reflecting improved profitability that could attract more investor interest.
- First Quarter Performance Growth: CTS reported a first-quarter net income of $17.20 million, or $0.59 per share, significantly up from $13.36 million and $0.44 per share last year, demonstrating enhanced competitiveness in the market.
- Significant Revenue Increase: The company achieved a 10.7% year-over-year revenue growth in the first quarter, reaching $139.23 million compared to $125.76 million last year, showcasing CTS's robust growth momentum in the industry.
See More
CTS Corporation Schedules Q1 2026 Earnings Release and Conference Call
- Earnings Release Schedule: CTS Corporation will release its Q1 2026 earnings on April 29, 2026, at 8:00 a.m. ET, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: A conference call is scheduled for the same day at 10:00 a.m. ET, providing management an opportunity to discuss the earnings results, which enhances market focus on the company's performance.
- Online Registration Access: Investors can register online to receive dial-in information and conference ID for the call, showcasing CTS's modernization in digital communication strategies.
- Company Background Information: CTS Corporation is a leading designer and manufacturer of sensors, actuators, and electronic components serving aerospace, industrial, medical, and transportation markets, demonstrating its strong competitive position across diverse sectors.
See More
CTS Corporation Declares Cash Dividend
- Dividend Declaration: CTS Corporation's Board of Directors has declared a cash dividend of $0.04 per share, scheduled for payment on April 24, 2026, to shareholders of record as of March 27, 2025, demonstrating the company's commitment to shareholder returns.
- Shareholder Return Strategy: This dividend reflects CTS's strong cash flow and profitability, aimed at boosting investor confidence and attracting more long-term investors to the stock.
- Market Positioning: As a leading manufacturer of sensors, actuators, and electronic components, CTS serves multiple markets including aerospace/defense, industrial, medical, and transportation, showcasing its diversified business model and market adaptability.
- Global Operations: With manufacturing capabilities in North America, Europe, and Asia, CTS is well-positioned to meet global customer demands, further solidifying its leadership in technological innovation and market competition.
See More
CTS Corporation Reports Strong Q4 2025 Earnings and 2026 Outlook
- Significant Revenue Growth: CTS Corporation reported fourth quarter sales of $137 million, reflecting a 9% year-over-year increase, with diversified market sales growing by 16%, demonstrating the successful implementation of the company's diversification strategy and strong market demand.
- Strong Medical Market Performance: The medical market saw a 41% year-over-year sales increase, highlighting robust growth momentum in therapeutic applications, which further solidifies CTS's market position in the healthcare sector.
- Margin Improvement: The adjusted gross margin for the fourth quarter reached 39.1%, up 150 basis points from the prior year, primarily driven by operational efficiencies and an improved market mix, enhancing the company's profitability.
- Optimistic 2026 Outlook: Management anticipates sales in the range of $550 million to $580 million for 2026, with adjusted EPS expected between $2.30 and $2.45, reflecting confidence in future market demand and ongoing product innovation.
See More
CTS Corporation Q1 2026 Earnings Call Insights
- Significant Sales Growth: CTS Corporation reported Q1 sales of $139 million, an 11% increase compared to Q1 2025, with diversified markets up 18% and transportation sales growing by 3%, indicating strong performance in diversified sectors.
- Margin Improvement: The adjusted diluted earnings per share for Q1 reached $0.62, up from $0.44 in Q1 2025, with gross margin expanding by 250 basis points to 39.5%, reflecting a notable enhancement in profitability.
- Strong Medical Market: Sales in the medical sector reached $25 million, a 28% year-over-year increase, indicating robust demand and an expectation for continued double-digit growth, which will further drive company performance.
- Tightened 2026 Outlook: The company narrowed its 2026 sales guidance to a range of $560 million to $580 million, with adjusted EPS expectations of $2.35 to $2.45, demonstrating management's confidence in future market conditions while maintaining cautious optimism regarding performance.
See More
CTS Corporation Q1 2026 Earnings Exceed Expectations
- Earnings Beat: CTS Corporation reported a Q1 2026 non-GAAP EPS of $0.62, exceeding estimates by $0.10, which reflects the company's strong profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved $139 million in revenue for the first quarter, marking a 10.3% year-over-year increase, with sales to diversified end-markets rising by 18%, indicating successful implementation of its market diversification strategy.
- Guidance Adjustment: CTS has narrowed its 2026 sales guidance from a range of $550-$580 million to $560-$580 million, while adjusting its diluted EPS forecast from $2.30-$2.45 to $2.35-$2.45, reflecting an optimistic outlook for future market conditions.
- Stable Transportation Market: Although sales in the transportation market grew by only 3%, CTS's strong performance in diversified markets demonstrates the effectiveness of its strategic positioning, laying a solid foundation for continued growth.
See More
CTS Corporation Narrows 2026 Sales Guidance
- Sales Guidance Adjustment: CTS Corporation has narrowed its 2026 sales guidance from $550-$580 million to $560-$580 million, indicating increased confidence in future market conditions, which may bolster investor sentiment.
- Earnings Per Share Upgrade: The company has revised its adjusted EPS forecast from $2.30-$2.45 to $2.35-$2.45, reflecting improved profitability that could attract more investor interest.
- First Quarter Performance Growth: CTS reported a first-quarter net income of $17.20 million, or $0.59 per share, significantly up from $13.36 million and $0.44 per share last year, demonstrating enhanced competitiveness in the market.
- Significant Revenue Increase: The company achieved a 10.7% year-over-year revenue growth in the first quarter, reaching $139.23 million compared to $125.76 million last year, showcasing CTS's robust growth momentum in the industry.
See More
CTS Corporation Schedules Q1 2026 Earnings Release and Conference Call
- Earnings Release Schedule: CTS Corporation will release its Q1 2026 earnings on April 29, 2026, at 8:00 a.m. ET, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: A conference call is scheduled for the same day at 10:00 a.m. ET, providing management an opportunity to discuss the earnings results, which enhances market focus on the company's performance.
- Online Registration Access: Investors can register online to receive dial-in information and conference ID for the call, showcasing CTS's modernization in digital communication strategies.
- Company Background Information: CTS Corporation is a leading designer and manufacturer of sensors, actuators, and electronic components serving aerospace, industrial, medical, and transportation markets, demonstrating its strong competitive position across diverse sectors.
See More
CTS Corporation Declares Cash Dividend
- Dividend Declaration: CTS Corporation's Board of Directors has declared a cash dividend of $0.04 per share, scheduled for payment on April 24, 2026, to shareholders of record as of March 27, 2025, demonstrating the company's commitment to shareholder returns.
- Shareholder Return Strategy: This dividend reflects CTS's strong cash flow and profitability, aimed at boosting investor confidence and attracting more long-term investors to the stock.
- Market Positioning: As a leading manufacturer of sensors, actuators, and electronic components, CTS serves multiple markets including aerospace/defense, industrial, medical, and transportation, showcasing its diversified business model and market adaptability.
- Global Operations: With manufacturing capabilities in North America, Europe, and Asia, CTS is well-positioned to meet global customer demands, further solidifying its leadership in technological innovation and market competition.
See More
CTS Corporation Reports Strong Q4 2025 Earnings and 2026 Outlook
- Significant Revenue Growth: CTS Corporation reported fourth quarter sales of $137 million, reflecting a 9% year-over-year increase, with diversified market sales growing by 16%, demonstrating the successful implementation of the company's diversification strategy and strong market demand.
- Strong Medical Market Performance: The medical market saw a 41% year-over-year sales increase, highlighting robust growth momentum in therapeutic applications, which further solidifies CTS's market position in the healthcare sector.
- Margin Improvement: The adjusted gross margin for the fourth quarter reached 39.1%, up 150 basis points from the prior year, primarily driven by operational efficiencies and an improved market mix, enhancing the company's profitability.
- Optimistic 2026 Outlook: Management anticipates sales in the range of $550 million to $580 million for 2026, with adjusted EPS expected between $2.30 and $2.45, reflecting confidence in future market demand and ongoing product innovation.
See More
